Blog Archives

The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs.  This year, the symposium will be a full-day program featuring a keynote by Dr. Peter Schulz, Scripps Research Institute.

This symposium will share the latest findings in the study of tumor metabolism, and how altered metabolic pathways can be targeted for cancer therapeutics.

Aging is the strongest risk factor for many serious diseases and co-morbidities, including cancer, heart disease, kidney disease, dementia, Alzheimer’s disease, frailty, and sarcopenia. Increasing evidence suggests that aging occurs in a regulated manner and that perturbation of discrete cell-signaling pathways can extend lifespan and delay age-related diseases and co-morbidities.  A number of key questions have surfaced through research efforts to better understand the molecular mechanisms underlying age-associated disease.  For example, what are the triggers for age-induced changes?  Which pathways are activated or suppressed as a result of age?  How could counter-regulating these pathways be used to treat established diseases that are age-related, or to improve co-morbidities which are age-associated?

This conference will bring scientists together from across academia and industry to examine these questions through a keynote and plenary talks on modeling aging in different systems, biomarkers and molecular clocks, disease processes and other age-related diseases, epigenetics and germline mutations, proteostasis and senescence, and secreted factors and reprogramming.  The concepts discussed in this symposium will help to drive work to improve treatments of age-related disorders.

The Ross Prize in Molecular Medicine was established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine. The 2022 virtual symposium celebrates the work of award winners — Katalin Karikó, PhD, and Drew Weissman, MD, PhD for their pioneering mRNA research. Presentations will also be delivered by other leaders in the field.

Developing targeted therapies for rare cardiomyopathies is challenging: difficulties identifying patients, delivering therapeutics, and accessing heart tissue results in a 50% mortality rate 5 years after diagnosis.  Early, accurate disease detection and classification can significantly improve outcomes for patients with rare cardiomyopathies. Achieving these goals requires multiple novel technologies to coalesce that will enable early patient identification, deepen our understanding of the disease process, improve modeling of human pathophysiology, accelerate testing of drug candidates, and leverage novel therapeutic modalities to target the heart specifically, safely and effectively.

This two-day conference will convene industry scientists, academics, and clinicians to understand the integration of artificial intelligence and engineered tissues for safe and effective delivery of novel therapeutics for patients with arrhythmogenic, hypertrophic, and dilated cardiomyopathies.

This three-day meeting will convene immuno-oncology experts across academia and industry to share cutting-edge discoveries and to advance the development of novel cancer immunotherapies.

The Frontiers in Cancer Immunotherapy 2024 symposium aims to explore innovative therapies in cancer treatment amidst the rapidly evolving field of cancer immunotherapy. Despite notable successes, challenges persist in understanding the biology of certain tumor types and identifying targets for novel therapies. The symposium provides a platform for researchers, clinicians, and industry leaders to discuss progress, potential, and advancements in drug therapies and technologies for improved cancer treatment.

Sponsors

---

Academy Friends